4-(2,3-二氯苯基)-1,4-二氢-2,6-二甲基-3,5-吡啶二甲酸甲基(1-丁酰氧基)甲酯

DMSO：≥50mg / mL（109.57 mM）

* “≥”表示可溶，但饱和度未知。

体内：1。逐个添加每种溶剂：10％DMSO 90％玉米油溶解度：≥2.5mg / mL（5.48 mM）;澄清溶液2.逐个加入各溶剂：10％DMSO 40％PEG300 5％吐温-80 45％盐水溶解度：≥2.5mg/ mL（5.48mM）;明确解决方案

4°C，避光

[1]. Yi X, Vivien B, Lynch C 3rd. Clevidipine blockade of L-type Ca2+ currents: steady-state and kinetic electrophysiological studies in guinea pigventricular myocytes.

[2]. Huraux C, Makita T, Szlam F, The vasodilator effects of clevidipine on human internal mammary artery. Anesth Analg. 1997 Nov;85(5):1000-4.

[3]. Ericsson H, et al. In vitro hydrolysis rate and protein binding of clevidipine, a new ultrashort-acting calcium antagonist metabolised by esterases, in different animal species and man. Eur J Pharm Sci. 1999 Apr;8(1):29-37.

[4]. Ericsson H, et al. Pharmacokinetics of new calcium channel antagonist clevidipine in the rat, rabbit, and dog and pharmacokinetic/pharmacodynamic relationship in anesthetized dogs. Drug Metab Dispos. 1999 May;27(5):558-64.

[5]. Schwieler JH, et al. Circulatory effects and pharmacology of clevidipine, a novel ultra short acting and vascular selective calcium antagonist, in hypertensive humans. J Cardiovasc Pharmacol. 1999 Aug;34(2):268-74.